Sukhatme Mayukh 4
Research Summary
AI-generated summary
Roivant (ROIV) President Mayukh Sukhatme Exercises Options, Sells Shares
What Happened
Mayukh Sukhatme, President & Chief Investment Officer and a director of Roivant Sciences (ROIV), exercised 651,558 stock options and on the same day disposed of the 651,558 underlying common shares. The exercise reported a weighted-average exercise price of $12.68 (total cost ≈ $8.26M). The shares were sold in two reported dispositions: 339,441 shares in open-market transactions at a weighted price of $26.47 (proceeds ≈ $8.99M) and 312,117 shares in an “other disposition” reported at $26.47 (proceeds ≈ $8.26M). Total gross sale proceeds were about $17.25M.
Key Details
- Transaction date: February 9, 2026 (reported on Form 4 filed Feb 11, 2026). No late filing noted in the report.
- Exercise: 651,558 options exercised (Code M) at a weighted-average price $12.68; exercise cost ≈ $8,261,755.
- Sales: 339,441 shares sold in open market (Code S) and 312,117 shares disposed (Code J), both reported at $26.47 (total sales ≈ $17,246,740). Footnote indicates sales executed at prices ranging $25.92–$26.78.
- Net/settlement detail: Footnotes state the issuer completed a “net settlement” of options to satisfy the exercise price (i.e., some shares were used to cover exercise/tax obligations). One derivative line at $0 reflects that net settlement.
- Footnotes: F1 notes the weighted-average price and offers to provide breakouts on request; F2 gives the sale-price range; F3 confirms net settlement by the issuer; F4 references a fully vested award.
- Shares owned after the transactions: not specified in the provided filing excerpt.
Context
- This was an options exercise followed by sales (a common practice when in-the-money options are exercised near expiration). Footnote F1 indicates the options would have expired in March 2026 if not exercised.
- The combination of exercise + immediate sale (including net settlement) typically reflects exercising options to capture intrinsic value and covering exercise/tax costs, rather than a new purchase signal. This Form 4 is factual reporting of those transactions and does not by itself indicate insider intent.